You just read:

TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer's and Frontotemporal Dementia

News provided by

TauRx Pharmaceuticals Ltd

08 Oct, 2015, 08:30 BST